Imgatuzumab

N/A

Report date: 2024/02/21 12:07:02

Base Information

Drug NameImgatuzumab
Drug Alias Name英加妥珠单抗imgatuzumabum英妥组单抗GA-201R-7160 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPoland +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlycart Biotechnology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche LtdPega-One
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG